The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,761.00
Bid: 1,757.50
Ask: 1,758.00
Change: 27.50 (1.59%)
Spread: 0.50 (0.028%)
Open: 1,736.00
High: 1,767.00
Low: 1,736.00
Prev. Close: 1,733.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET OPEN: Glaxo To Co-Develop Covid Vaccine; Vodafone Rises

Wed, 03rd Feb 2021 08:47

(Alliance News) - Stock prices in London opened higher on Wednesday driven by progress over a US stimulus deal and on tackling the coronavirus pandemic.

The FTSE 100 index was up 52.26 points, or 0.8%, at 6,568.91. The mid-cap FTSE 250 index was up 163.89 points, or 0.8%, at 20,854.23. The AIM All-Share index was up 0.5% at 1,194.91.

The Cboe UK 100 index was up 0.8% at 653.35. The Cboe 250 was up 0.8% at 18,407.31 and the Cboe Small Companies was flat at 12,230.54.

In mainland Europe, the CAC 40 in Paris was up 0.8% while the DAX 30 in Frankfurt was up 1.4%.

UK drugmaker GlaxoSmithKline and German biopharmaceutical company CureVac announced a new EUR150 million collaboration to jointly develop next-generation mRNA vaccines for Covid-19, with the potential for a "multi-valent approach" to address multiple emerging variants in one vaccine.

Under the terms of the collaboration agreement, Glaxo will have exclusive rights to develop, manufacture, and commercialise the vaccine in all countries with the exception of Germany, Austria and Switzerland. It also will be the marketing authorisation holder for all countries other than Switzerland. Glaxo will make an upfront payment to CureVac of EUR75 million and a further milestone payment of EUR75 million, conditional on the achievement of specific milestones.

Further, Glaxo will also support the manufacture of up to 100 million doses of CureVac's first generation Covid-19 vaccine candidate CVnCoV in 2021.

GlaxoSmithKline will report annual results at midday on Wednesday. The stock was up 0.7%.

In the FTSE 100, Vodafone was the best performer, up 3.7%, after the telecommunications firm said it returned to organic service revenue growth in its third-quarter, helped by a much stronger showing in Germany.

Total revenue in the quarter ended December 31 fell 4.7% to EUR11.20 billion from EUR11.75 billion a year earlier. The organic figure - which strips out the effects M&A activity and currency movements - was 0.4%.

Vodafone generates the bulk of its cash from service revenue, which includes monthly access charges, airtime usage and roaming. In the third quarter ended December, service revenue rose 0.4% on an organic basis. The organic service revenue figure is one that is closely eyed by analysts.

In Germany alone, service revenue rose 1.0% year-on-year on both an organic and reported basis to EUR2.91 billion.

Richard Hunter, head of markets at interactive investor, commented: "Any improvements in a company of Vodafone's size are likely to be incremental, and the latest set of figures build on the progress being made...Despite the challenges, Vodafone remains a cash generating behemoth, with its multi-million customer base making a powerful cumulative contribution to income."

Aviva was up 3.4% after Morgan Stanley upgraded the insurer to Overweight from Equal Weight.

Taylor Wimpey and Persimmon were up 2.5% and 2.2% respectively after Barclays upgraded both housebuilders to Overweight from Equal Weight.

Ferguson rose 1.5% after the plumbing and heating products supplier said it is in the process of registering with the US Securities & Exchange Commission to enable trading of its ordinary shares in the US.

Ferguson anticipates that the additional US listing will become effective in early March and confirmed that it has applied to list its ordinary shares on the New York Stock Exchange. In addition, Ferguson will retain its premium listing on the London Stock Exchange and inclusion in the FTSE 100 index.

At the other end of the large caps, Glencore was 0.5% lower. The commodities house reported declines in annual copper, cobalt and coal output but increases in the two precious metals, gold and silver.

Copper production fell by 8% in 2020 to 1.26 million tonnes from 1.37 million, though Glencore said copper output was steady on 2019 when excluding Mutanda, which is currently on care and maintenance.

Cobalt production dropped 41% to 27,400 ounces from 46,300 ounces, and coal by 24% to 106.2 million tonnes from 139.5 million in 2019. However, gold output rose by 3% to 916,000 ounces in 2020 from 886,000 and silver by 2% to 32.8 million ounces from 32.0 million.

The Japanese Nikkei 225 index closed up 1.0%. In China, the Shanghai Composite ended down 0.5%, while the Hang Seng index in Hong Kong ended 0.3% lower. The S&P/ASX 200 in Sydney closed up 0.9%.

The pound was quoted at USD1.3675 on Wednesday morning, higher from USD1.3644 at the London equities close Tuesday.

The euro stood at USD1.2038, up from USD1.2029. Against the yen, the dollar was trading at JPY105.07, little changed from JPY105.05.

Brent oil was quoted at USD58.03 a barrel Wednesday morning, up from USD57.58 at the London market close Tuesday. Gold was trading at USD1,839.65 an ounce, a touch higher from USD1,837.20 late Tuesday.

In the economics calendar on Wednesday, there are French, German, eurozone and UK service PMI readings at 0850 GMT, 0855 GMT, 0900 GMT and 0930 GMT, respectively. In the afternoon, the US service PMI print is at 1445 GMT. Elsewhere, the eurozone consumer and producer price index is due at 1000 GMT.

By Arvind Bhunjun; arvindbhunjun@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
18 Dec 2023 07:18

GSK sees success in Jemperli endometrial cancer trial

(Sharecast News) - GSK released positive headline results from the planned analysis of its trial of Jemperli in endometrial cancer on Monday.

Read more
17 Dec 2023 15:16

PRESS: GSK looks for deals in China as rebuilds relationship

(Alliance News) - The Financial Times on Sunday reported that GSK PLC is looking for some new deals in China.

Read more
15 Dec 2023 17:08

European shares end fifth week higher on rate-cut optimism

Barclays sees first ECB rate cut in April

*

Read more
15 Dec 2023 16:51

LONDON MARKET CLOSE: FTSE 100 underperforms as post-Fed rally cools

(Alliance News) - London's FTSE 100 ended lower on Friday, with profit-taking and some hawkish words from a US policymaker keeping equities in check at the end of a largely positive week for stocks.

Read more
15 Dec 2023 16:29

PRESS: GSK, Astra and AbbVie in US scrutiny over patents - Bloomberg

(Alliance News) - A US senator has accused AstraZeneca PLC, GSK PLC, AbbVie Inc and other drugmakers of "abusing" the patent system to send prices higher, Bloomberg reported on Thursday.

Read more
12 Dec 2023 10:08

AstraZeneca buys respiratory vaccine developer Icosavax in $1.1 bln deal

Dec 12 (Reuters) - AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion.

Read more
12 Dec 2023 08:22

TOP NEWS: Japan accepts GSK's filing for respiratory disease vaccine

(Alliance News) - GSK PLC on Tuesday said Japan's Ministry of Health, Labour & Welfare has accepted its regulatory application for the extension of its respiratory syncytial virus vaccine, Arexvy, for adults aged 50-59.

Read more
12 Dec 2023 07:39

LONDON BRIEFING: UK unemployment unchanged at 4.2%; eyes on US CPI

(Alliance News) - Stocks in London are called to open higher, as investors digest the latest UK unemployment data, before turning their heads to US inflation.

Read more
12 Dec 2023 07:24

GSK seeks to extend RSV vaccine approval in Japan

(Sharecast News) - GSK announced on Tuesday that Japan's Ministry of Health, Labour and Welfare (MHLW) has accepted its regulatory application for the extension of the indication of its RSV vaccine to include adults aged 50- to 59 at an increased risk of contracting the disease.

Read more
11 Dec 2023 08:28

GSK drug gets EU marketing backing for form of endometrial cancer

(Alliance News) - GSK PLC on Monday said it won EU backing for its Jemperli drug in tandem with chemotherapy to treat a form of endometrial cancer.

Read more
11 Dec 2023 07:41

LONDON BRIEFING: GSK drug gets EU endorsement; Begbies backs outlook

(Alliance News) - London's FTSE 100 is called to open a touch lower on Monday, kicking off the week with some slight trepidation after Friday's hotter-than-expected US jobs report which offered the dollar some respite.

Read more
11 Dec 2023 07:23

GSK endometrial cancer treatment gets Europe authorisation

(Sharecast News) - GSK announced on Monday that the European Commission has granted marketing authorisation for 'Jemperli', or dostarlimab, in combination with chemotherapy for certain endometrial cancers.

Read more
7 Dec 2023 12:54

THG backer Kelso pushes for demerger to trim "inherent" valuation gap

(Alliance News) - THG PLC investor Kelso Group Holdings PLC on Thursday reiterated its call for a demerger, which the shareholder believes will help close the "disparity" between the e-commerce firm's share price and its true value.

Read more
5 Dec 2023 10:02

LONDON BROKER RATINGS: Goldman lifts Landsec and British Land

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
27 Nov 2023 09:00

GSK announces positive results from Blenrep phase 3 blood cancer trial

(Alliance News) - GSK PLC on Monday said a phase 3 trial of belantamab mafodotin as a multiple myeloma treatment has produced positive headline results.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.